Carregant...
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against key community-acquired bacterial pneumonia (CABP) pathogens. However, the clinical efficacy and safety of lefamulin for treating CABP remains unclear. An integrated analysis of 2 phase III trials investigating the cl...
Guardat en:
| Publicat a: | Medicine (Baltimore) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer Health
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7373590/ https://ncbi.nlm.nih.gov/pubmed/32702892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021223 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|